Millennium Management LLC Purchases 58,052 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Millennium Management LLC boosted its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 10.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 634,968 shares of the company's stock after buying an additional 58,052 shares during the period. Millennium Management LLC owned approximately 0.43% of MiMedx Group worth $6,108,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Invesco Ltd. lifted its holdings in MiMedx Group by 2.2% in the fourth quarter. Invesco Ltd. now owns 56,565 shares of the company's stock valued at $544,000 after buying an additional 1,226 shares during the period. Tower Research Capital LLC TRC lifted its holdings in MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after buying an additional 2,837 shares during the period. IMG Wealth Management Inc. acquired a new position in MiMedx Group in the fourth quarter valued at $28,000. Bank of New York Mellon Corp lifted its holdings in MiMedx Group by 0.7% in the fourth quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company's stock valued at $4,849,000 after buying an additional 3,300 shares during the period. Finally, Van ECK Associates Corp acquired a new position in MiMedx Group in the fourth quarter valued at $40,000. Institutional investors and hedge funds own 79.15% of the company's stock.

MiMedx Group Stock Up 0.6%

Shares of NASDAQ MDXG traded up $0.04 during trading on Thursday, hitting $6.55. 339,756 shares of the company traded hands, compared to its average volume of 690,713. The business's fifty day moving average is $7.00 and its 200 day moving average is $8.15. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The firm has a market capitalization of $967.45 million, a price-to-earnings ratio of 11.91 and a beta of 1.85. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The firm had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. Equities research analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO William Frank Iv Hulse sold 81,446 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the sale, the chief accounting officer now owns 494,774 shares in the company, valued at $3,859,237.20. This represents a 14.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Joseph H. Capper bought 200,000 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was acquired at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the acquisition, the chief executive officer now directly owns 529,530 shares in the company, valued at $3,357,220.20. The trade was a 60.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 144,018 shares of company stock worth $1,130,312 in the last quarter. Insiders own 1.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MDXG. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th. Wall Street Zen lowered shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday, May 9th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.